Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel...

ALEXION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ALXN and Encourages Investors to Contact the Firm NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...

ALXN ALERT: Rosen Law Firm Reminds Alexion Pharmaceuticals, Inc. Investors of Important January 17 Deadline in Class Action – ALXN NEW YORK, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Alexion Pharmaceuticals, Inc. securities (NASDAQ:ALXN) from February 10, 2014...

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alexion Pharmaceuticals, Inc. – ALXN NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Alexion Pharmaceuticals, Inc....